Veracyte (VCYT) Financials

$27.61 -1.20 (-4.17%)

Closing price 05/21/2025 04:00 PM Eastern

Extended Trading

$27.40 -0.21 (-0.76%)

As of 07:56 AM Eastern

Annual Income Statements for Veracyte

This table shows Veracyte's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	24	-74	-37	-76	-35	-13	-23	-31	-31	-34
Consolidated Net Income / (Loss)	24	-74	-37	-76	-35	-13	-23	-31	-31	-34
Net Income / (Loss) Continuing Operations	24	-74	-37	-76	-35	-13	-23	-31	-31	-34
Total Pre-Tax Income	26	-77	-36	-82	-35	-13	-23	-31	-32	-34
Total Operating Income	16	-86	-41	-82	-35	-15	-22	-27	-29	-33
Total Gross Profit	298	230	176	145	76	84	59	44	40	28
Total Revenue	446	361	297	220	117	120	92	72	65	50
Operating Revenue	446	361	297	220	117	120	92	72	65	50
Total Cost of Revenue	148	131	121	74	41	37	33	28	25	21
Operating Cost of Revenue	136	113	102	74	41	37	33	28	25	21
Total Operating Expenses	294	334	236	227	111	99	81	70	68	61
Selling, General & Admin Expense	111	86	73	101	37	29	24	23	24	23
Marketing Expense	95	101	98	80	52	54	41	32	28	25
Research & Development Expense	69	57	41	30	17	15	15	14	15	13
Amortization Expense	15	21	21	16	5.10	1.40	1.07	1.07	1.07	0.80
Impairment Charge	3.37	68	3.32	0.00	-	-	-	-	-	-
Total Other Income / (Expense), net	9.60	9.18	4.65	0.25	0.48	2.53	-0.77	-4.94	-2.76	-0.38
Other Income / (Expense), net	9.60	9.18	4.65	0.25	0.48	2.53	1.20	-	-	-
Income Tax Expense	1.61	-2.21	0.13	-6.09	0.00	0.00	-	-	-	-
Basic Earnings per Share	$0.32	($1.02)	($0.51)	($1.11)	($0.66)	($0.27)	($0.62)	($0.91)	($1.09)	($1.30)
Weighted Average Basic Shares Outstanding	76.48M	72.64M	71.55M	67.89M	53.24M	46.14M	37.02M	33.93M	28.83M	25.99M
Diluted Earnings per Share	$0.31	($1.02)	($0.51)	($1.11)	($0.66)	($0.27)	($0.62)	($0.91)	($1.09)	($1.30)
Weighted Average Diluted Shares Outstanding	78.16M	72.64M	71.55M	67.89M	53.24M	46.14M	37.02M	33.93M	28.83M	25.99M
Weighted Average Basic & Diluted Shares Outstanding	77.94M	75.07M	72.15M	71.22M	53.24M	46.14M	37.02M	33.93M	28.83M	25.99M

This table shows Veracyte's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	7.05	5.11	15	5.73	-1.86	-28	-30	-8.40	-8.09	-3.84	-8.72
Consolidated Net Income / (Loss)	7.05	5.11	15	5.73	-1.86	-28	-30	-8.40	-8.09	-3.84	-8.72
Net Income / (Loss) Continuing Operations	7.05	5.11	15	5.73	-1.86	-28	-30	-8.40	-8.09	-3.84	-8.72
Total Pre-Tax Income	7.43	3.44	17	7.36	-1.91	-30	-30	-8.28	-8.09	-3.44	-8.88
Total Operating Income	2.90	4.18	12	4.61	-4.66	-36	-32	-8.05	-10	-5.42	-9.68
Total Gross Profit	80	76	79	78	65	60	58	56	56	34	50
Total Revenue	114	119	116	114	97	98	90	90	82	80	76
Operating Revenue	114	119	116	114	97	98	90	90	82	80	76
Total Cost of Revenue	35	43	37	37	31	38	32	35	26	46	26
Operating Cost of Revenue	32	37	34	34	31	29	28	30	26	27	26
Total Operating Expenses	79	77	70	76	70	104	94	69	67	59	59
Selling, General & Admin Expense	34	27	26	32	26	24	16	25	21	15	18
Marketing Expense	24	25	23	24	24	25	24	26	26	24	26
Research & Development Expense	18	19	18	16	16	19	13	13	13	11	11
Amortization Expense	3.21	3.61	3.80	3.79	3.65	4.56	5.34	5.34	5.33	5.26	5.21
Impairment Charge	0.00	2.75	0.19	0.00	0.43	32	35	0.00	1.41	-	0.00
Total Other Income / (Expense), net	4.52	-0.73	4.83	2.76	2.75	5.04	1.97	-0.23	2.41	1.98	0.81
Other Income / (Expense), net	4.52	-0.73	4.83	2.76	2.75	5.04	1.97	-0.23	2.41	1.98	0.81
Income Tax Expense	0.38	-1.67	1.69	1.63	-0.04	-2.18	-0.15	0.13	0.00	0.40	-0.15
Basic Earnings per Share	$0.09	$0.07	$0.20	$0.07	($0.02)	($0.38)	($0.41)	($0.12)	($0.11)	($0.06)	($0.12)
Weighted Average Basic Shares Outstanding	78.03M	76.48M	77.01M	76.54M	74.76M	72.64M	72.80M	72.48M	72.18M	71.55M	71.66M
Diluted Earnings per Share	$0.09	$0.07	$0.19	$0.07	($0.02)	($0.38)	($0.41)	($0.12)	($0.11)	($0.06)	($0.12)
Weighted Average Diluted Shares Outstanding	80.06M	78.16M	78.46M	77.16M	74.76M	72.64M	72.80M	72.48M	72.18M	71.55M	71.66M
Weighted Average Basic & Diluted Shares Outstanding	78.31M	77.94M	77.50M	76.81M	76.45M	75.07M	73.04M	-	72.75M	72.15M	71.75M

This table details how cash moves in and out of Veracyte's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	23	62	-19	-176	190	81	44	-25	20	4.07
Net Cash From Operating Activities	75	44	7.54	-32	-9.71	-3.23	-14	-24	-28	-27
Net Cash From Continuing Operating Activities	75	44	7.54	-32	-9.71	-3.23	-14	-24	-28	-27
Net Income / (Loss) Continuing Operations	24	-74	-37	-76	-35	-13	-23	-31	-31	-34
Consolidated Net Income / (Loss)	24	-74	-37	-76	-35	-13	-23	-31	-31	-34
Depreciation Expense	23	27	26	20	7.94	4.12	3.92	3.84	3.51	2.25
Non-Cash Adjustments To Reconcile Net Income	47	105	34	26	16	11	6.18	8.22	7.05	5.79
Changes in Operating Assets and Liabilities, net	-19	-13	-16	-1.23	1.03	-5.88	-0.65	-5.44	-6.41	-1.35
Net Cash From Investing Activities	-56	15	-29	-739	-3.84	-43	-1.87	-1.32	-4.21	-6.70
Net Cash From Continuing Investing Activities	-56	15	-29	-739	-3.84	-43	-1.87	-1.32	-4.21	-6.70
Purchase of Property, Plant & Equipment	-11	-9.96	-8.55	-5.38	-2.84	-2.76	-1.87	-1.76	-4.21	-6.17
Acquisitions	5.01	0.00	0.00	-737	0.00	-40	0.00	0.00	-	0.00
Purchase of Investments	-50	-20	-34	0.00	-1.00	0.00	0.00	-	-	-
Sale and/or Maturity of Investments	0.00	45	13	0.00	0.00	-	-	-	-	-
Net Cash From Financing Activities	4.90	2.84	3.49	596	204	127	59	-0.22	52	38
Net Cash From Continuing Financing Activities	4.90	2.84	3.49	596	204	127	59	-0.22	52	38
Repayment of Debt	0.00	0.00	-1.28	0.00	-0.10	-25	0.00	-26	-5.00	0.00
Other Financing Activities, net	4.90	2.84	4.78	2.50	9.86	14	4.46	0.36	0.93	0.48
Effect of Exchange Rate Changes	-0.42	0.16	-0.59	-1.51	0.00	-	-	-	-	-
Cash Interest Paid	0.00	0.00	0.01	0.01	0.01	0.33	1.55	2.72	2.15	0.28
Cash Income Taxes Paid	2.24	1.70	0.57	0.11	0.11	0.04	0.08	0.02	0.01	0.02

This table details how cash moves in and out of Veracyte's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-53	-35	38	27	-7.06	14	11	13	24	-16	17
Net Cash From Operating Activities	5.36	25	30	30	-8.97	16	14	17	-2.17	9.74	7.03
Net Cash From Continuing Operating Activities	5.36	25	30	30	-8.97	16	14	17	-2.17	9.74	7.03
Net Income / (Loss) Continuing Operations	7.05	5.11	15	5.73	-1.86	-28	-30	-8.40	-8.09	-3.84	-8.72
Consolidated Net Income / (Loss)	7.05	5.11	15	5.73	-1.86	-28	-30	-8.40	-8.09	-3.84	-8.72
Depreciation Expense	5.36	6.25	5.88	5.74	5.59	6.34	7.32	6.86	6.67	6.56	6.32
Non-Cash Adjustments To Reconcile Net Income	10	17	8.66	11	10	39	44	12	10	6.79	9.11
Changes in Operating Assets and Liabilities, net	-17	-3.52	0.28	6.80	-23	-1.45	-7.67	6.69	-11	0.24	0.32
Net Cash From Investing Activities	-52	-54	-2.24	-2.77	2.88	-2.50	-2.80	-3.67	24	-26	8.81
Net Cash From Continuing Investing Activities	-52	-54	-2.24	-2.77	2.88	-2.50	-2.80	-3.67	24	-26	8.81
Purchase of Property, Plant & Equipment	-1.82	-4.14	-2.24	-2.77	-2.13	-2.50	-2.80	-3.67	-0.99	-1.87	-1.71
Acquisitions	0.00	-	-	-	5.01	-	-	-	0.00	-	-
Purchase of Investments	-50	-50	-	-	0.00	-	-	-	-20	-25	-
Net Cash From Financing Activities	-6.48	-4.51	10	-0.01	-0.86	0.65	0.11	0.40	1.69	0.09	1.49
Net Cash From Continuing Financing Activities	-6.48	-4.51	10	-0.01	-0.86	0.65	0.11	0.40	1.69	0.09	1.49
Other Financing Activities, net	-6.48	-4.51	10	-0.01	-0.86	0.65	0.11	0.40	1.69	1.28	1.48
Effect of Exchange Rate Changes	0.07	-0.40	0.15	-0.06	-0.11	0.30	-0.18	-0.01	0.05	0.73	-0.65
Cash Income Taxes Paid	0.12	1.03	1.19	-	-	0.43	1.27	-	-	0.14	0.37

This table presents Veracyte's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	1,300	1,115	1,156	1,188	457	275	121	79	101	75
Total Current Assets	372	286	249	243	376	188	97	54	74	48
Cash & Equivalents	239	216	154	173	349	159	78	34	59	39
Short-Term Investments	50	0.00	25	3.96	-	-	-	-	-	-
Accounts Receivable	47	40	44	41	18	19	13	13	8.76	3.50
Inventories, net	22	16	14	11	4.66	6.81	3.40	5.32	3.48	3.77
Prepaid Expenses	15	13	11	13	3.20	2.24	2.39	2.00	2.06	1.44
Plant, Property, & Equipment, net	23	21	18	15	8.99	8.93	8.94	9.69	11	10
Total Noncurrent Assets	905	809	890	930	72	79	15	15	16	17
Goodwill	746	703	696	708	2.73	2.73	1.06	1.06	1.06	1.06
Intangible Assets	102	89	175	203	60	65	12	13	14	15
Other Noncurrent Operating Assets	55	16	19	18	9.24	10	1.09	0.33	0.13	0.16
Other Noncurrent Nonoperating Assets	1.54	0.88	0.75	0.75	0.60	0.60	0.60	0.60	0.60	0.60
Total Liabilities & Shareholders' Equity	1,300	1,115	1,156	1,188	457	275	121	79	101	75
Total Liabilities	124	71	81	91	36	36	41	41	41	24
Total Current Liabilities	79	61	63	64	17	17	13	12	12	15
Short-Term Debt	17	2.66	6.06	3.81	0.00	1.41	1.36	0.00	-	-
Accounts Payable	8.63	13	12	12	3.12	2.33	2.52	3.85	2.42	5.09
Accrued Expenses	44	38	38	39	12	14	9.19	8.18	9.11	8.69
Current Deferred Revenue	1.67	2.01	2.61	4.65	0.37	0.00	-	-	-	0.95
Other Current Liabilities	7.52	5.21	4.26	3.86	1.59	-	0.00	-	-	-
Total Noncurrent Liabilities	45	9.56	19	27	19	18	28	29	30	9.27
Noncurrent Deferred & Payable Income Tax Liabilities	1.23	0.73	4.53	5.59	0.00	-	-	-	-	-
Other Noncurrent Operating Liabilities	44	8.83	14	21	18	18	0.00	-	-	-
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,176	1,044	1,075	1,097	421	239	80	37	60	51
Total Preferred & Common Equity	1,176	1,044	1,075	1,097	421	239	80	37	60	51
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,176	1,044	1,075	1,097	421	239	80	37	60	51
Common Stock	1,656	1,536	1,500	1,469	703	486	314	248	240	200
Retained Earnings	-444	-468	-394	-357	-282	-247	-234	-211	-180	-149
Accumulated Other Comprehensive Income / (Loss)	-36	-24	-31	-15	0.00	-	-	-	-	-

This table presents Veracyte's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	9/30/2022
Total Assets	1,315	1,275	1,234	1,200	1,125	1,161	1,126
Total Current Assets	383	357	321	290	271	259	239
Cash & Equivalents	186	274	236	209	202	191	170
Short-Term Investments	101	-	-	-	0.00	0.00	0.00
Accounts Receivable	54	49	50	47	39	42	40
Inventories, net	24	20	19	18	16	12	14
Prepaid Expenses	18	14	16	16	14	14	15
Plant, Property, & Equipment, net	23	21	22	22	19	19	17
Total Noncurrent Assets	910	897	891	888	834	883	870
Goodwill	754	762	752	754	693	699	677
Intangible Assets	99	109	113	116	124	165	177
Other Noncurrent Operating Assets	55	25	25	17	17	19	16
Other Noncurrent Nonoperating Assets	1.65	1.08	1.09	1.08	0.87	0.89	0.75
Total Liabilities & Shareholders' Equity	1,315	1,275	1,234	1,200	1,125	1,161	1,126
Total Liabilities	120	99	102	81	71	78	78
Total Current Liabilities	75	70	72	58	57	58	58
Short-Term Debt	14	7.39	7.35	6.93	2.57	3.36	7.10
Accounts Payable	16	9.67	12	12	13	13	11
Accrued Expenses	36	44	43	30	35	34	32
Current Deferred Revenue	1.71	2.03	2.20	2.60	2.21	2.38	3.86
Other Current Liabilities	7.42	7.35	7.26	6.07	5.11	5.09	4.14
Total Noncurrent Liabilities	45	29	29	23	14	20	19
Noncurrent Deferred & Payable Income Tax Liabilities	1.24	1.47	1.48	1.34	3.64	4.71	4.34
Other Noncurrent Operating Liabilities	44	27	28	22	9.98	16	15
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,195	1,176	1,133	1,119	1,054	1,083	1,048
Total Preferred & Common Equity	1,195	1,176	1,133	1,119	1,054	1,083	1,048
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,195	1,176	1,133	1,119	1,054	1,083	1,048
Common Stock	1,661	1,646	1,627	1,618	1,528	1,521	1,492
Retained Earnings	-437	-449	-464	-470	-440	-410	-390
Accumulated Other Comprehensive Income / (Loss)	-29	-21	-31	-29	-34	-28	-54

This table displays calculated financial ratios and metrics derived from Veracyte's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	23.46%	21.76%	35.09%	86.85%	-2.40%	30.82%	27.87%	10.55%	31.48%	29.62%
EBITDA Growth	199.55%	-370.75%	83.08%	-130.14%	-221.05%	50.84%	23.13%	14.74%	16.36%	-12.48%
EBIT Growth	133.60%	-110.32%	55.39%	-133.89%	-177.08%	40.11%	20.73%	7.86%	13.93%	-15.38%
NOPAT Growth	125.20%	-108.84%	49.84%	-131.44%	-133.95%	31.96%	16.22%	7.86%	13.93%	-15.38%
Net Income Growth	132.44%	-103.51%	51.62%	-116.46%	-177.08%	45.22%	25.82%	1.13%	6.96%	-14.74%
EPS Growth	130.39%	-100.00%	54.05%	-68.18%	-144.44%	56.45%	31.87%	16.51%	16.15%	4.41%
Operating Cash Flow Growth	69.82%	486.89%	123.83%	-225.62%	-200.46%	76.10%	43.46%	14.53%	-3.77%	2.41%
Free Cash Flow Firm Growth	-571.50%	252.12%	99.12%	-5,867.08%	75.42%	-245.27%	16.23%	25.91%	-0.39%	30.50%
Invested Capital Growth	8.74%	-8.01%	-2.25%	1,179.80%	-11.71%	169.09%	8.44%	11.21%	53.05%	48.15%
Revenue Q/Q Growth	4.80%	5.22%	4.57%	17.57%	4.27%	3.42%	7.17%	1.90%	6.92%	3.87%
EBITDA Q/Q Growth	220.10%	-122.90%	52.75%	0.60%	4.76%	-37.91%	18.07%	-4.54%	12.26%	1.11%
EBIT Q/Q Growth	415.07%	-54.52%	24.10%	-5.16%	1.70%	-26.15%	16.59%	-9.82%	12.93%	0.32%
NOPAT Q/Q Growth	191.85%	-54.01%	14.40%	-5.49%	0.35%	-51.47%	11.84%	-9.82%	12.93%	0.32%
Net Income Q/Q Growth	360.44%	-48.94%	15.46%	-3.40%	-1.71%	-52.79%	18.83%	-14.97%	10.32%	0.38%
EPS Q/Q Growth	321.43%	-45.71%	10.53%	0.00%	4.35%	-58.82%	23.46%	-13.75%	12.80%	5.11%
Operating Cash Flow Q/Q Growth	13.57%	15.12%	20.81%	16.36%	4.63%	48.27%	25.34%	-7.09%	-5.27%	17.21%
Free Cash Flow Firm Q/Q Growth	19.67%	254.49%	-128.57%	1.45%	77.89%	-283.20%	-2.45%	-2.68%	2.61%	5.39%
Invested Capital Q/Q Growth	-0.69%	-2.80%	1.95%	-2.50%	-9.16%	130.62%	15.62%	5.99%	11.93%	2.89%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	66.88%	63.62%	59.24%	66.11%	64.71%	69.66%	64.05%	60.81%	60.88%	56.57%
EBITDA Margin	11.04%	-13.69%	-3.54%	-28.27%	-22.95%	-6.98%	-18.57%	-30.89%	-40.05%	-62.96%
Operating Margin	3.62%	-23.76%	-13.85%	-37.31%	-30.12%	-12.57%	-24.16%	-36.88%	-44.25%	-67.60%
EBIT Margin	5.78%	-21.22%	-12.28%	-37.20%	-29.71%	-10.47%	-22.86%	-36.88%	-44.25%	-67.60%
Profit (Net Income) Margin	5.42%	-20.61%	-12.33%	-34.42%	-29.71%	-10.47%	-25.00%	-43.09%	-48.18%	-68.08%
Tax Burden Percent	93.76%	97.12%	100.37%	92.55%	100.00%	100.00%	100.00%	98.49%	99.36%	99.59%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	109.33%	118.62%	109.57%	101.13%
Effective Tax Rate	6.24%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	1.75%	-6.94%	-3.15%	-11.53%	-32.23%	-18.91%	-53.38%	-69.92%	-96.95%	-170.17%
ROIC Less NNEP Spread (ROIC-NNEP)	-1.94%	0.45%	1.34%	-4.56%	-28.23%	-16.97%	-28.03%	-13.02%	-64.61%	-138.60%
Return on Net Nonoperating Assets (RNNOA)	0.43%	-0.08%	-0.21%	1.57%	21.66%	11.02%	14.05%	5.87%	40.36%	97.40%
Return on Equity (ROE)	2.17%	-7.02%	-3.37%	-9.96%	-10.57%	-7.89%	-39.32%	-64.05%	-56.59%	-72.77%
Cash Return on Invested Capital (CROIC)	-6.63%	1.41%	-0.88%	-182.54%	-19.79%	-110.54%	-61.47%	-80.54%	-138.87%	-208.98%
Operating Return on Assets (OROA)	2.13%	-6.75%	-3.11%	-9.93%	-9.53%	-6.37%	-21.11%	-29.54%	-32.68%	-47.78%
Return on Assets (ROA)	2.00%	-6.55%	-3.12%	-9.19%	-9.53%	-6.37%	-23.08%	-34.50%	-35.58%	-48.12%
Return on Common Equity (ROCE)	2.17%	-7.02%	-3.37%	-9.96%	-10.57%	-7.89%	-39.32%	-64.05%	-56.59%	-72.77%
Return on Equity Simple (ROE_SIMPLE)	2.05%	-7.13%	-3.40%	-6.89%	-8.29%	-5.26%	-28.84%	-83.29%	-52.63%	-65.76%
Net Operating Profit after Tax (NOPAT)	15	-60	-29	-57	-25	-11	-16	-19	-20	-23
NOPAT Margin	3.40%	-16.63%	-9.70%	-26.12%	-21.09%	-8.80%	-16.91%	-25.82%	-30.98%	-47.32%
Net Nonoperating Expense Percent (NNEP)	3.68%	-7.39%	-4.49%	-6.97%	-4.00%	-1.94%	-25.35%	-56.91%	-32.34%	-31.58%
Return On Investment Capital (ROIC_SIMPLE)	1.27%	-5.74%	-2.66%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	33.12%	36.38%	40.76%	33.89%	35.29%	30.34%	35.95%	39.19%	39.12%	43.43%
SG&A Expenses to Revenue	24.81%	23.88%	24.69%	46.17%	31.26%	24.12%	26.04%	32.09%	36.55%	45.62%
R&D to Revenue	15.55%	15.87%	13.69%	13.60%	14.64%	12.34%	16.11%	19.29%	23.54%	25.85%
Operating Expenses to Revenue	65.85%	92.49%	79.60%	103.42%	94.84%	82.22%	88.21%	97.70%	105.13%	124.18%
Earnings before Interest and Taxes (EBIT)	26	-77	-36	-82	-35	-13	-21	-27	-29	-33
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	49	-49	-10	-62	-27	-8.40	-17	-22	-26	-31
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.61	1.92	1.58	2.67	6.73	5.69	6.39	5.97	3.63	3.89
Price to Tangible Book Value (P/TBV)	9.36	7.96	8.33	15.75	7.90	7.94	7.65	9.62	4.87	5.69
Price to Revenue (P/Rev)	6.88	5.57	5.74	13.33	24.12	11.33	5.54	3.09	3.32	4.02
Price to Earnings (P/E)	127.14	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.79%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	3.10	2.16	1.70	2.99	34.48	14.78	15.20	7.64	7.26	10.04
Enterprise Value to Revenue (EV/Rev)	6.27	4.97	5.16	12.54	21.15	10.02	5.01	2.97	2.80	3.33
Enterprise Value to EBITDA (EV/EBITDA)	56.84	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	108.63	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	184.77	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	37.24	40.60	203.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	147.49	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.01	0.00	0.01	0.00	0.00	0.01	0.37	0.68	0.43	0.10
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.35	0.68	0.43	0.10
Financial Leverage	-0.22	-0.18	-0.16	-0.34	-0.77	-0.65	-0.50	-0.45	-0.62	-0.70
Leverage Ratio	1.09	1.07	1.08	1.08	1.11	1.24	1.70	1.86	1.59	1.51
Compound Leverage Factor	1.09	1.07	1.08	1.08	1.11	1.24	1.86	2.20	1.74	1.53
Debt to Total Capital	1.42%	0.25%	0.56%	0.35%	0.19%	0.87%	26.79%	40.41%	29.99%	8.87%
Short-Term Debt to Total Capital	1.42%	0.25%	0.56%	0.35%	0.00%	0.58%	1.25%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.19%	0.29%	25.54%	40.41%	29.99%	8.87%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	98.58%	99.75%	99.44%	99.65%	99.81%	99.13%	73.21%	59.59%	70.01%	91.13%
Debt to EBITDA	0.35	-0.05	-0.58	-0.06	-0.03	-0.25	-1.71	-1.14	-0.98	-0.16
Net Debt to EBITDA	-5.54	4.33	16.46	2.79	12.93	18.72	2.86	0.39	1.30	1.10
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	-0.03	-0.08	-1.63	-1.14	-0.98	-0.16
Debt to NOPAT	1.12	-0.04	-0.21	-0.07	-0.03	-0.20	-1.88	-1.36	-1.27	-0.21
Net Debt to NOPAT	-18.00	3.56	6.01	3.02	14.07	14.85	3.14	0.47	1.68	1.46
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	-0.03	-0.07	-1.79	-1.36	-1.27	-0.21
Altman Z-Score	15.04	16.78	12.45	18.95	47.40	22.66	5.79	-0.10	1.08	1.93
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.73	4.66	3.97	3.79	22.39	10.74	7.42	4.48	6.38	3.25
Quick Ratio	4.27	4.19	3.56	3.41	21.92	10.23	6.98	3.87	5.89	2.89
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-57	12	-8.00	-908	-15	-62	-18	-21	-29	-29
Operating Cash Flow to CapEx	665.33%	443.95%	88.14%	-588.19%	-342.30%	-118.26%	-721.50%	-1,818.63%	-664.66%	-437.39%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	-9.13	-4.33	-10.48	-76.11
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	-6.89	-4.84	-10.15	-71.34
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	-7.84	-5.11	-11.68	-87.65
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.37	0.32	0.25	0.27	0.32	0.61	0.92	0.80	0.74	0.71
Accounts Receivable Turnover	10.26	8.56	6.94	7.33	6.22	7.41	7.11	6.70	10.62	15.11
Inventory Turnover	7.79	8.64	9.47	9.37	7.23	7.16	7.58	6.41	7.03	5.76
Fixed Asset Turnover	20.48	18.86	18.08	18.23	13.11	13.47	9.88	6.80	5.97	6.84
Accounts Payable Turnover	13.68	10.57	9.96	9.61	15.23	15.08	10.39	8.98	6.78	3.44
Days Sales Outstanding (DSO)	35.58	42.66	52.61	49.82	58.70	49.27	51.34	54.46	34.37	24.16
Days Inventory Outstanding (DIO)	46.83	42.26	38.54	38.96	50.46	51.01	48.14	56.95	51.91	63.36
Days Payable Outstanding (DPO)	26.68	34.53	36.65	37.96	23.97	24.20	35.14	40.63	53.82	105.97
Cash Conversion Cycle (CCC)	55.73	50.40	54.49	50.81	85.20	76.07	64.35	70.79	32.46	-18.45
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	902	829	902	922	72	82	30	28	25	16
Invested Capital Turnover	0.51	0.42	0.33	0.44	1.53	2.15	3.16	2.71	3.13	3.60
Increase / (Decrease) in Invested Capital	73	-72	-21	850	-9.56	51	2.36	2.82	8.72	5.34
Enterprise Value (EV)	2,797	1,796	1,530	2,754	2,485	1,206	461	214	183	165
Market Capitalization	3,069	2,009	1,703	2,927	2,833	1,364	510	222	216	199
Book Value per Share	$15.17	$14.30	$14.98	$15.43	$7.28	$4.90	$1.97	$1.09	$2.13	$1.85
Tangible Book Value per Share	$4.23	$3.46	$2.85	$2.62	$6.19	$3.52	$1.65	$0.68	$1.59	$1.26
Total Capital	1,193	1,047	1,081	1,100	422	242	109	62	85	56
Total Debt	17	2.66	6.06	3.81	0.81	2.10	29	25	26	4.99
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.81	0.69	28	25	26	4.99
Net Debt	-272	-214	-173	-173	-349	-157	-49	-8.65	-34	-34
Capital Expenditures (CapEx)	11	9.96	8.55	5.38	2.84	2.73	1.87	1.32	4.21	6.17
Debt-free, Cash-free Net Working Capital (DFCFNWC)	21	11	13	5.60	9.53	12	7.26	8.01	2.75	-6.01
Debt-free Net Working Capital (DFNWC)	311	227	192	183	359	172	85	42	62	33
Net Working Capital (NWC)	294	224	186	179	359	170	84	42	62	33
Net Nonoperating Expense (NNE)	-9.00	14	7.80	18	10	2.01	7.44	12	11	10
Net Nonoperating Obligations (NNO)	-274	-215	-174	-174	-349	-158	-49	-9.25	-34	-35
Total Depreciation and Amortization (D&A)	23	27	26	20	7.94	4.20	3.95	4.31	2.74	2.30
Debt-free, Cash-free Net Working Capital to Revenue	4.75%	2.93%	4.46%	2.55%	8.12%	10.23%	7.89%	11.13%	4.23%	-12.14%
Debt-free Net Working Capital to Revenue	69.68%	62.88%	64.78%	83.26%	305.49%	142.58%	92.66%	58.23%	95.40%	67.05%
Net Working Capital to Revenue	65.87%	62.15%	62.73%	81.52%	305.49%	141.41%	91.18%	58.23%	95.40%	67.05%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.32	($1.02)	($0.51)	($1.11)	($0.66)	($0.27)	($0.62)	($0.91)	($1.09)	($1.30)
Adjusted Weighted Average Basic Shares Outstanding	76.48M	72.64M	71.55M	67.89M	67.00M	49.74M	41.11M	34.29M	33.85M	27.85M
Adjusted Diluted Earnings per Share	$0.31	($1.02)	($0.51)	($1.11)	($0.66)	($0.27)	($0.62)	($0.91)	($1.09)	($1.30)
Adjusted Weighted Average Diluted Shares Outstanding	78.16M	72.64M	71.55M	67.89M	67.00M	49.74M	41.11M	34.29M	33.85M	27.85M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	($0.66)	($0.27)	($0.62)	($0.91)	($1.09)	($1.30)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	77.94M	75.07M	72.15M	71.22M	53.24M	46.14M	37.02M	33.93M	28.83M	25.99M
Normalized Net Operating Profit after Tax (NOPAT)	18	-12	-26	-57	-25	-11	-16	-19	-20	-23
Normalized NOPAT Margin	4.10%	-3.38%	-8.91%	-26.12%	-21.09%	-8.80%	-16.91%	-25.82%	-30.98%	-47.32%
Pre Tax Income Margin	5.78%	-21.22%	-12.28%	-37.20%	-29.71%	-10.47%	-25.00%	-43.75%	-48.49%	-68.37%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	-10.72	-5.37	-10.45	-88.53
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	-7.93	-3.76	-7.31	-61.97
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	-11.67	-5.64	-11.97	-104.84
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	-8.88	-4.03	-8.84	-78.28
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Veracyte's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	18.20%	20.81%	28.58%	26.69%	17.50%	22.29%	19.20%	23.96%	21.60%	19.25%	25.21%
EBITDA Growth	247.37%	140.17%	201.23%	1,023.77%	359.11%	-874.83%	-780.01%	55.06%	82.03%	152.54%	72.69%
EBIT Growth	489.31%	111.30%	156.59%	188.93%	76.42%	-785.56%	-235.46%	14.20%	44.06%	72.10%	42.66%
NOPAT Growth	184.53%	124.95%	148.65%	163.66%	55.65%	-555.11%	-227.88%	24.99%	31.15%	56.05%	41.97%
Net Income Growth	478.06%	118.07%	151.17%	168.25%	76.96%	-636.03%	-239.54%	11.85%	44.05%	63.49%	38.26%
EPS Growth	550.00%	118.42%	146.34%	158.33%	81.82%	-533.33%	-241.67%	7.69%	45.00%	50.00%	40.00%
Operating Cash Flow Growth	159.80%	57.69%	111.44%	77.40%	-312.80%	59.61%	101.69%	4,692.56%	75.52%	15.37%	604.38%
Free Cash Flow Firm Growth	90.92%	-240.02%	-596.30%	-199.82%	-205.66%	179.33%	-83.77%	437.58%	108.32%	101.97%	106.24%
Invested Capital Growth	0.54%	8.74%	6.44%	0.00%	2.38%	-8.01%	-3.52%	0.00%	-3.31%	-2.25%	-6.51%
Revenue Q/Q Growth	-3.51%	2.39%	1.25%	18.16%	-1.38%	8.98%	-0.24%	9.58%	2.65%	6.22%	3.74%
EBITDA Q/Q Growth	31.91%	-57.34%	73.49%	255.76%	115.26%	-7.51%	-1,483.15%	0.21%	-145.62%	222.11%	19.14%
EBIT Q/Q Growth	115.74%	-79.56%	128.88%	485.80%	93.74%	-2.35%	-259.70%	-2.30%	-135.14%	61.23%	8.00%
NOPAT Q/Q Growth	-55.56%	-42.64%	201.27%	210.09%	86.89%	-11.87%	-294.22%	23.31%	-93.69%	44.01%	9.81%
Net Income Q/Q Growth	37.83%	-66.26%	164.30%	407.62%	93.41%	4.47%	-252.51%	-3.84%	-110.48%	55.93%	8.49%
EPS Q/Q Growth	28.57%	-63.16%	171.43%	450.00%	94.74%	7.32%	-241.67%	-9.09%	-83.33%	50.00%	7.69%
Operating Cash Flow Q/Q Growth	-78.14%	-18.15%	1.31%	429.86%	-157.65%	9.75%	-15.00%	867.54%	-122.29%	38.68%	2,035.54%
Free Cash Flow Firm Q/Q Growth	96.64%	-50.20%	95.09%	-3,566.61%	-151.77%	432.38%	-99.01%	3,780.95%	36.87%	-69.07%	120.55%
Invested Capital Q/Q Growth	2.03%	-0.69%	0.60%	-1.36%	10.35%	-2.80%	0.00%	-100.00%	-0.84%	1.95%	-2.44%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	69.46%	63.93%	68.19%	68.09%	67.51%	61.08%	64.02%	61.80%	68.18%	42.58%	65.59%
EBITDA Margin	11.17%	8.17%	19.62%	11.45%	3.80%	-24.58%	-24.91%	-1.57%	-1.72%	3.88%	-3.37%
Operating Margin	2.54%	3.52%	10.37%	4.03%	-4.81%	-36.16%	-35.22%	-8.91%	-12.74%	-6.75%	-12.81%
EBIT Margin	6.49%	2.90%	14.54%	6.43%	-1.97%	-31.03%	-33.04%	-9.16%	-9.82%	-4.29%	-11.74%
Profit (Net Income) Margin	6.16%	4.31%	13.08%	5.01%	-1.92%	-28.81%	-32.87%	-9.30%	-9.82%	-4.79%	-11.54%
Tax Burden Percent	94.87%	148.50%	89.95%	77.90%	97.69%	92.85%	99.48%	101.51%	100.00%	111.71%	98.29%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	5.13%	-48.50%	10.05%	22.10%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	1.22%	2.69%	4.51%	2.78%	-1.40%	-10.56%	-9.74%	0.00%	-3.05%	-1.54%	-2.78%
ROIC Less NNEP Spread (ROIC-NNEP)	-0.58%	3.14%	2.65%	0.91%	-2.11%	-8.79%	-5.68%	0.00%	-2.63%	-1.51%	-1.58%
Return on Net Nonoperating Assets (RNNOA)	0.12%	-0.69%	-0.56%	-0.18%	0.38%	1.61%	0.98%	0.00%	0.42%	0.24%	0.24%
Return on Equity (ROE)	1.34%	2.00%	3.95%	2.59%	-1.02%	-8.95%	-8.75%	0.00%	-2.63%	-1.29%	-2.54%
Cash Return on Invested Capital (CROIC)	1.89%	-6.63%	-8.11%	-210.44%	-8.54%	1.41%	-0.91%	0.00%	0.56%	-0.88%	3.06%
Operating Return on Assets (OROA)	2.39%	1.07%	5.15%	2.08%	-0.63%	-9.87%	-10.07%	0.00%	-2.62%	-1.08%	-2.88%
Return on Assets (ROA)	2.27%	1.59%	4.64%	1.62%	-0.61%	-9.16%	-10.02%	0.00%	-2.62%	-1.21%	-2.83%
Return on Common Equity (ROCE)	1.34%	2.00%	3.95%	2.59%	-1.02%	-8.95%	-8.75%	0.00%	-2.63%	-1.29%	-2.54%
Return on Equity Simple (ROE_SIMPLE)	2.77%	0.00%	-0.79%	-4.77%	-6.09%	0.00%	-4.74%	0.00%	-2.79%	0.00%	-4.13%
Net Operating Profit after Tax (NOPAT)	2.76	6.20	11	3.59	-3.26	-25	-22	-5.64	-7.35	-3.79	-6.78
NOPAT Margin	2.41%	5.23%	9.33%	3.14%	-3.37%	-25.31%	-24.66%	-6.24%	-8.92%	-4.73%	-8.96%
Net Nonoperating Expense Percent (NNEP)	1.80%	-0.44%	1.86%	1.87%	0.71%	-1.77%	-4.06%	0.00%	-0.43%	-0.03%	-1.20%
Return On Investment Capital (ROIC_SIMPLE)	0.23%	0.52%	-	-	-	-2.37%	-	-	-	-0.35%	-
Cost of Revenue to Revenue	30.54%	36.07%	31.81%	31.91%	32.49%	38.92%	35.98%	38.20%	31.82%	57.42%	34.41%
SG&A Expenses to Revenue	29.53%	22.69%	22.22%	27.74%	27.06%	24.23%	18.13%	27.73%	25.54%	18.54%	23.28%
R&D to Revenue	15.48%	16.26%	15.17%	14.39%	16.49%	19.02%	14.78%	13.88%	15.49%	14.06%	14.25%
Operating Expenses to Revenue	69.18%	65.24%	60.34%	66.61%	72.32%	106.24%	104.58%	76.04%	80.91%	73.34%	78.40%
Earnings before Interest and Taxes (EBIT)	7.43	3.44	17	7.36	-1.91	-30	-30	-8.28	-8.09	-3.44	-8.88
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	13	9.70	23	13	3.68	-24	-22	-1.42	-1.42	3.12	-2.55
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.93	2.61	2.22	1.46	1.49	1.92	1.54	0.00	1.49	1.58	1.13
Price to Tangible Book Value (P/TBV)	6.77	9.36	8.57	6.18	6.70	7.96	6.85	0.00	7.34	8.33	6.10
Price to Revenue (P/Rev)	4.99	6.88	6.15	4.15	4.43	5.57	4.73	5.61	5.17	5.74	4.19
Price to Earnings (P/E)	69.93	127.14	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	1.43%	0.79%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.21	3.10	2.59	1.58	1.60	2.16	1.67	0.00	1.59	1.70	1.16
Enterprise Value to Revenue (EV/Rev)	4.40	6.27	5.52	3.57	3.89	4.97	4.15	0.00	4.57	5.16	3.62
Enterprise Value to EBITDA (EV/EBITDA)	34.95	56.84	152.76	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	58.10	108.63	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	91.27	184.77	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	22.79	37.24	35.51	28.37	39.04	40.60	37.09	0.00	99.84	203.04	164.37
Enterprise Value to Free Cash Flow (EV/FCFF)	117.49	0.00	0.00	0.00	0.00	147.49	0.00	0.00	277.01	0.00	36.60
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.01	0.01	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.01	0.01
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.21	-0.22	-0.21	-0.20	-0.18	-0.18	-0.17	0.00	-0.16	-0.16	-0.15
Leverage Ratio	1.09	1.09	1.08	1.09	1.07	1.07	1.07	0.00	1.08	1.08	1.07
Compound Leverage Factor	1.09	1.09	1.08	1.09	1.07	1.07	1.07	0.00	1.08	1.08	1.07
Debt to Total Capital	1.19%	1.42%	0.62%	0.64%	0.62%	0.25%	0.24%	0.00%	0.31%	0.56%	0.67%
Short-Term Debt to Total Capital	1.19%	1.42%	0.62%	0.64%	0.62%	0.25%	0.24%	0.00%	0.31%	0.56%	0.67%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	98.81%	98.58%	99.38%	99.36%	99.38%	99.75%	99.76%	0.00%	99.69%	99.44%	99.33%
Debt to EBITDA	0.25	0.35	0.48	-0.25	-0.16	-0.05	-0.12	0.00	-0.84	-0.58	-0.32
Net Debt to EBITDA	-4.68	-5.54	-17.35	7.67	4.56	4.33	9.02	0.00	46.81	16.46	7.34
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.64	1.12	-0.45	-0.16	-0.12	-0.04	-0.07	0.00	-0.13	-0.21	-0.21
Net Debt to NOPAT	-12.23	-18.00	16.18	4.85	3.61	3.56	5.13	0.00	7.38	6.01	4.85
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	11.70	14.99	16.00	9.82	12.25	16.91	13.65	0.00	12.27	12.54	9.10
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.10	4.73	5.08	4.44	5.00	4.66	4.74	0.00	4.46	3.97	4.09
Quick Ratio	4.54	4.27	4.59	3.96	4.41	4.19	4.22	0.00	4.02	3.56	3.60
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-2.23	-66	-44	-899	-25	47	8.90	901	23	17	55
Operating Cash Flow to CapEx	294.78%	592.22%	1,336.44%	1,067.69%	-420.15%	622.83%	505.75%	454.37%	-218.73%	520.51%	409.92%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.37	0.37	0.35	0.32	0.32	0.32	0.30	0.00	0.27	0.25	0.25
Accounts Receivable Turnover	9.23	10.26	9.66	7.94	8.43	8.56	8.65	0.00	7.34	6.94	7.06
Inventory Turnover	6.96	7.79	6.87	6.24	7.90	8.64	8.08	0.00	8.70	9.47	8.27
Fixed Asset Turnover	21.02	20.48	21.01	17.93	18.74	18.86	18.79	0.00	17.88	18.08	0.00
Accounts Payable Turnover	10.64	13.68	11.22	9.94	9.43	10.57	10.15	0.00	8.61	9.96	8.75
Days Sales Outstanding (DSO)	39.56	35.58	37.80	45.95	43.27	42.66	42.21	0.00	49.76	52.61	51.73
Days Inventory Outstanding (DIO)	52.43	46.83	53.11	58.50	46.19	42.26	45.15	0.00	41.98	38.54	44.16
Days Payable Outstanding (DPO)	34.31	26.68	32.52	36.71	38.69	34.53	35.97	0.00	42.37	36.65	41.71
Cash Conversion Cycle (CCC)	57.69	55.73	58.39	67.74	50.77	50.40	51.40	0.00	49.37	54.49	54.17
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	920	902	908	903	915	829	853	0.00	894	902	884
Invested Capital Turnover	0.50	0.51	0.48	0.89	0.42	0.42	0.39	0.00	0.34	0.33	0.31
Increase / (Decrease) in Invested Capital	4.98	73	55	903	21	-72	-31	-907	-31	-21	-62
Enterprise Value (EV)	2,038	2,797	2,348	1,428	1,461	1,796	1,425	0.00	1,421	1,530	1,025
Market Capitalization	2,311	3,069	2,615	1,657	1,664	2,009	1,625	1,844	1,609	1,703	1,188
Book Value per Share	$15.33	$15.17	$15.31	$14.81	$14.90	$14.30	$14.49	$0.00	$15.01	$14.98	$14.64
Tangible Book Value per Share	$4.38	$4.23	$3.97	$3.50	$3.31	$3.46	$3.26	$0.00	$3.04	$2.85	$2.72
Total Capital	1,209	1,193	1,183	1,140	1,126	1,047	1,057	0.00	1,086	1,081	1,055
Total Debt	14	17	7.39	7.35	6.93	2.66	2.57	0.00	3.36	6.06	7.10
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-273	-272	-267	-229	-202	-214	-200	0.00	-188	-173	-163
Capital Expenditures (CapEx)	1.82	4.14	2.24	2.77	2.13	2.50	2.80	3.67	0.99	1.87	1.71
Debt-free, Cash-free Net Working Capital (DFCFNWC)	35	21	20	20	30	11	14	0.00	14	13	17
Debt-free Net Working Capital (DFNWC)	322	311	294	256	239	227	216	0.00	205	192	187
Net Working Capital (NWC)	308	294	287	249	232	224	214	0.00	201	186	180
Net Nonoperating Expense (NNE)	-4.29	1.09	-4.35	-2.15	-1.40	3.44	7.40	2.77	0.74	0.05	1.95
Net Nonoperating Obligations (NNO)	-275	-274	-268	-230	-203	-215	-201	0.00	-189	-174	-164
Total Depreciation and Amortization (D&A)	5.36	6.25	5.88	5.74	5.59	6.34	7.32	6.86	6.67	6.56	6.32
Debt-free, Cash-free Net Working Capital to Revenue	7.56%	4.75%	4.67%	5.06%	8.02%	2.93%	4.08%	0.00%	4.35%	4.46%	6.05%
Debt-free Net Working Capital to Revenue	69.57%	69.68%	69.11%	64.10%	63.73%	62.88%	63.09%	0.00%	65.78%	64.78%	66.04%
Net Working Capital to Revenue	66.47%	65.87%	67.37%	62.26%	61.89%	62.15%	62.34%	0.00%	64.70%	62.73%	63.53%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.09	$0.07	$0.20	$0.07	($0.02)	($0.38)	($0.41)	$0.00	$0.00	($0.06)	($0.12)
Adjusted Weighted Average Basic Shares Outstanding	78.03M	76.48M	77.01M	76.54M	74.76M	72.64M	72.80M	0.00	0.00	71.55M	71.66M
Adjusted Diluted Earnings per Share	$0.09	$0.07	$0.19	$0.07	($0.02)	($0.38)	($0.41)	$0.00	$0.00	($0.06)	($0.12)
Adjusted Weighted Average Diluted Shares Outstanding	80.06M	78.16M	78.46M	77.16M	74.76M	72.64M	72.80M	0.00	0.00	71.55M	71.66M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	78.31M	77.94M	77.50M	76.81M	76.45M	75.07M	73.04M	0.00	0.00	72.15M	71.75M
Normalized Net Operating Profit after Tax (NOPAT)	2.76	4.85	11	3.59	-2.96	-2.43	2.21	-5.64	-6.36	-3.79	-6.78
Normalized NOPAT Margin	2.41%	4.09%	9.47%	3.14%	-3.06%	-2.47%	2.46%	-6.24%	-7.72%	-4.73%	-8.96%
Pre Tax Income Margin	6.49%	2.90%	14.54%	6.43%	-1.97%	-31.03%	-33.04%	-9.16%	-9.82%	-4.29%	-11.74%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Veracyte's Financials

When does Veracyte's financial year end?

According to the most recent income statement we have on file, Veracyte's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Veracyte's net income changed over the last 9 years?

Over the last 9 years, Veracyte's net income changed from -$33.70 million in 2015 to $24.14 million in 2024, a change of -171.6%. See where experts think Veracyte is headed by visiting Veracyte's forecast page.

What is Veracyte's operating income?

Veracyte's total operating income in 2024 was $16.14 million, based on the following breakdown:

Total Gross Profit: $298.15 million
Total Operating Expenses: $293.56 million

How has Veracyte revenue changed over the last 9 years?

Over the last 9 years, Veracyte's total revenue changed from $49.50 million in 2015 to $445.76 million in 2024, a change of 800.5%.

How much debt does Veracyte have?

Veracyte's total liabilities were at $124.07 million at the end of 2024, a 75.2% increase from 2023, and a 417.1% increase since 2015.

How much cash does Veracyte have?

In the past 9 years, Veracyte's cash and equivalents has ranged from $33.89 million in 2017 to $349.36 million in 2020, and is currently $239.09 million as of their latest financial filing in 2024.

How has Veracyte's book value per share changed over the last 9 years?

Over the last 9 years, Veracyte's book value per share changed from 1.85 in 2015 to 15.17 in 2024, a change of 719.1%.

Related Companies

This page (NASDAQ:VCYT) was last updated on 5/22/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veracyte (VCYT) Financials

Frequently Asked Questions About Veracyte's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Veracyte (VCYT) Financials

Annual Income Statements for Veracyte

Quarterly Income Statements for Veracyte

Annual Cash Flow Statements for Veracyte

Quarterly Cash Flow Statements for Veracyte

Annual Balance Sheets for Veracyte

Quarterly Balance Sheets for Veracyte

Annual Metrics And Ratios for Veracyte

Quarterly Metrics And Ratios for Veracyte

Frequently Asked Questions About Veracyte's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools